Cargando…

RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers

BACKGROUND: Runt-related transcription factor 1 (RUNX1) is a vital regulator of mammalian expression. Despite multiple pieces of evidence indicating that dysregulation of RUNX1 is a common phenomenon in human cancers, there is no evidence from pan-cancer analysis. METHODS: We comprehensively investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuo, Zhouting, Zhang, Ying, Wang, Xin, Dai, Shuxin, Liu, Kun, Xia, Dian, Wang, Jinyou, Bi, Liangkuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088136/
https://www.ncbi.nlm.nih.gov/pubmed/35534796
http://dx.doi.org/10.1186/s12885-022-09632-y
_version_ 1784704304200810496
author Tuo, Zhouting
Zhang, Ying
Wang, Xin
Dai, Shuxin
Liu, Kun
Xia, Dian
Wang, Jinyou
Bi, Liangkuan
author_facet Tuo, Zhouting
Zhang, Ying
Wang, Xin
Dai, Shuxin
Liu, Kun
Xia, Dian
Wang, Jinyou
Bi, Liangkuan
author_sort Tuo, Zhouting
collection PubMed
description BACKGROUND: Runt-related transcription factor 1 (RUNX1) is a vital regulator of mammalian expression. Despite multiple pieces of evidence indicating that dysregulation of RUNX1 is a common phenomenon in human cancers, there is no evidence from pan-cancer analysis. METHODS: We comprehensively investigated the effect of RUNX1 expression on tumor prognosis across human malignancies by analyzing multiple cancer-related databases, including Gent2, Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), the Human Protein Atlas (HPA), UALCAN, PrognoScan, cBioPortal, STRING, and Metascape. RESULTS: Bioinformatics data indicated that RUNX1 was overexpressed in most of these human malignancies and was significantly associated with the prognosis of patients with cancer. Immunohistochemical results showed that most cancer tissues were moderately positive for granular cytoplasm, and RUNX1 was expressed at a medium level in four types of tumors, including cervical cancer, colorectal cancer, glioma, and renal cancer. RUNX1 expression was positively correlated with infiltrating levels of cancer-associated fibroblasts (CAFs) in 33 different cancers. Moreover, RUNX1 expression may influence patient prognosis by activating oncogenic signaling pathways in human cancers. CONCLUSION: Our findings suggest that RUNX1 expression correlates with patient outcomes and immune infiltrate levels of CAFs in multiple tumors. Additionally, the increased level of RUNX1 was linked to the activation of oncogenic signaling pathways in human cancers, suggesting a potential role of RUNX1 among cancer therapeutic targets. These findings suggest that RUNX1 can function as a potential prognostic biomarker and reflect the levels of immune infiltrates of CAFs in human cancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09632-y.
format Online
Article
Text
id pubmed-9088136
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90881362022-05-11 RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers Tuo, Zhouting Zhang, Ying Wang, Xin Dai, Shuxin Liu, Kun Xia, Dian Wang, Jinyou Bi, Liangkuan BMC Cancer Research BACKGROUND: Runt-related transcription factor 1 (RUNX1) is a vital regulator of mammalian expression. Despite multiple pieces of evidence indicating that dysregulation of RUNX1 is a common phenomenon in human cancers, there is no evidence from pan-cancer analysis. METHODS: We comprehensively investigated the effect of RUNX1 expression on tumor prognosis across human malignancies by analyzing multiple cancer-related databases, including Gent2, Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA), the Human Protein Atlas (HPA), UALCAN, PrognoScan, cBioPortal, STRING, and Metascape. RESULTS: Bioinformatics data indicated that RUNX1 was overexpressed in most of these human malignancies and was significantly associated with the prognosis of patients with cancer. Immunohistochemical results showed that most cancer tissues were moderately positive for granular cytoplasm, and RUNX1 was expressed at a medium level in four types of tumors, including cervical cancer, colorectal cancer, glioma, and renal cancer. RUNX1 expression was positively correlated with infiltrating levels of cancer-associated fibroblasts (CAFs) in 33 different cancers. Moreover, RUNX1 expression may influence patient prognosis by activating oncogenic signaling pathways in human cancers. CONCLUSION: Our findings suggest that RUNX1 expression correlates with patient outcomes and immune infiltrate levels of CAFs in multiple tumors. Additionally, the increased level of RUNX1 was linked to the activation of oncogenic signaling pathways in human cancers, suggesting a potential role of RUNX1 among cancer therapeutic targets. These findings suggest that RUNX1 can function as a potential prognostic biomarker and reflect the levels of immune infiltrates of CAFs in human cancers. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-09632-y. BioMed Central 2022-05-09 /pmc/articles/PMC9088136/ /pubmed/35534796 http://dx.doi.org/10.1186/s12885-022-09632-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tuo, Zhouting
Zhang, Ying
Wang, Xin
Dai, Shuxin
Liu, Kun
Xia, Dian
Wang, Jinyou
Bi, Liangkuan
RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers
title RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers
title_full RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers
title_fullStr RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers
title_full_unstemmed RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers
title_short RUNX1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers
title_sort runx1 is a promising prognostic biomarker and related to immune infiltrates of cancer-associated fibroblasts in human cancers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088136/
https://www.ncbi.nlm.nih.gov/pubmed/35534796
http://dx.doi.org/10.1186/s12885-022-09632-y
work_keys_str_mv AT tuozhouting runx1isapromisingprognosticbiomarkerandrelatedtoimmuneinfiltratesofcancerassociatedfibroblastsinhumancancers
AT zhangying runx1isapromisingprognosticbiomarkerandrelatedtoimmuneinfiltratesofcancerassociatedfibroblastsinhumancancers
AT wangxin runx1isapromisingprognosticbiomarkerandrelatedtoimmuneinfiltratesofcancerassociatedfibroblastsinhumancancers
AT daishuxin runx1isapromisingprognosticbiomarkerandrelatedtoimmuneinfiltratesofcancerassociatedfibroblastsinhumancancers
AT liukun runx1isapromisingprognosticbiomarkerandrelatedtoimmuneinfiltratesofcancerassociatedfibroblastsinhumancancers
AT xiadian runx1isapromisingprognosticbiomarkerandrelatedtoimmuneinfiltratesofcancerassociatedfibroblastsinhumancancers
AT wangjinyou runx1isapromisingprognosticbiomarkerandrelatedtoimmuneinfiltratesofcancerassociatedfibroblastsinhumancancers
AT biliangkuan runx1isapromisingprognosticbiomarkerandrelatedtoimmuneinfiltratesofcancerassociatedfibroblastsinhumancancers